Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 824

1.

Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of Phase 3 ASTRAL trials.

Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ.

Clin Infect Dis. 2016 Aug 23. pii: ciw579. [Epub ahead of print]

PMID:
27553377
2.

The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.

Vermehren J, Peiffer KH, Welsch C, Grammatikos G, Welker MW, Weiler N, Zeuzem S, Welzel TM, Sarrazin C.

Aliment Pharmacol Ther. 2016 Aug 23. doi: 10.1111/apt.13769. [Epub ahead of print]

PMID:
27549000
3.

Preclinical Profile and Clinical Efficacy of a Novel HCV NS5A Inhibitor, EDP-239.

Owens CM, Brasher BB, Polemeropoulos A, Rhodin MH, McAllister N, Peng X, Wang C, Ying L, Cao H, Lawitz E, Poordad F, Rondon J, Box TD, Zeuzem S, Buggisch P, Lin K, Qiu YL, Jiang L, Colvin R, Or YS.

Antimicrob Agents Chemother. 2016 Aug 8. pii: AAC.00808-16. [Epub ahead of print]

PMID:
27503640
4.

Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.

Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, Friedrich-Rust M, Sarrazin C, Zeuzem S, Welker MW.

J Viral Hepat. 2016 Aug 8. doi: 10.1111/jvh.12578. [Epub ahead of print]

PMID:
27500382
5.

Role of CD15 expression in dysplastic and neoplastic tissue of the bile duct - a potential novel tool for differential diagnosis of indeterminate biliary stricture.

Walter D, Herrmann E, Winkelmann R, Albert JG, Liese J, Schnitzbauer A, Zeuzem S, Hansmann ML, Peveling-Oberhag J, Hartmann S.

Histopathology. 2016 Jul 21. doi: 10.1111/his.13041. [Epub ahead of print]

PMID:
27442966
6.

[Expert recommendations: Hepatitis C and transplantation].

Zimmermann T, Beckebaum S, Berg C, Berg T, Braun F, Eurich D, Herzer K, Neumann U, Rupp C, Sterneck M, Strassburg C, Welker MW, Zachoval R, Gotthardt DN, Weigand K, Schmidt H, Wedemeyer H, Galle PR, Zeuzem S, Sarrazin C.

Z Gastroenterol. 2016 Jul;54(7):665-84. doi: 10.1055/s-0042-107360. Epub 2016 Jul 18. German.

PMID:
27429106
7.

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.

Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group.

Gut. 2016 Jul 13. pii: gutjnl-2016-311609. doi: 10.1136/gutjnl-2016-311609. [Epub ahead of print]

8.

Pre- and Post-Transplant Antiviral Therapy (HBV, HCV).

Welker MW, Zeuzem S.

Visc Med. 2016 Apr;32(2):105-9. doi: 10.1159/000445152. Epub 2016 Apr 8. Review.

PMID:
27413727
9.

Viral Hepatitis and Its Complications.

Zeuzem S, Bechstein WO.

Visc Med. 2016 Apr;32(2):78. doi: 10.1159/000445984. Epub 2016 Apr 15. No abstract available.

PMID:
27413723
10.

Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy.

Piratvisuth T, Komolmit P, Chan HL, Tanwandee T, Sukeepaisarnjaroen W, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J, Zeuzem S, Manns M, Uddin A, Dong Y, Trylesinski A.

Drugs Context. 2016 Apr 22;5:212294. doi: 10.7573/dic.212294. eCollection 2016.

11.

Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.

Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, Manns MP, Sherman K, Frazier LM, Sterling R, Mailliard M, Schmidt M, Akushevich L, Vainorius M, Fried MW.

Clin Infect Dis. 2016 Jun 19. pii: ciw387. [Epub ahead of print]

PMID:
27325691
12.

Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels.

Grammatikos G, Dietz J, Ferreiros N, Koch A, Dultz G, Bon D, Karakasiliotis I, Lutz T, Knecht G, Gute P, Herrmann E, Zeuzem S, Mavromara P, Sarrazin C, Pfeilschifter J.

Int J Mol Sci. 2016 Jun 13;17(6). pii: E922. doi: 10.3390/ijms17060922.

13.

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.

Dietz J, Rupp D, Susser S, Vermehren J, Peiffer KH, Filmann N, Bon D, Kuntzen T, Mauss S, Grammatikos G, Perner D, Berkowski C, Herrmann E, Zeuzem S, Bartenschlager R, Sarrazin C.

PLoS One. 2016 Jun 9;11(6):e0156731. doi: 10.1371/journal.pone.0156731. eCollection 2016.

14.

Differential Kinetics of Coagulation Factors and Natural Anticoagulants in Patients with Liver Cirrhosis: Potential Clinical Implications.

Tischendorf M, Miesbach W, Chattah U, Chattah Z, Maier S, Welsch C, Zeuzem S, Lange CM.

PLoS One. 2016 May 12;11(5):e0155337. doi: 10.1371/journal.pone.0155337. eCollection 2016.

15.

Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.

Zeuzem S, Mantry P, Soriano V, Buynak RJ, Dufour JF, Pockros PJ, Wright D, Angus P, Buti M, Stern JO, Kadus W, Vinisko R, Böcher W, Mensa FJ.

Eur J Gastroenterol Hepatol. 2016 Aug;28(8):923-6. doi: 10.1097/MEG.0000000000000649.

PMID:
27140229
16.

Sofosbuvir and Velpatasvir for Patients with HCV Infection.

Feld JJ, Zeuzem S.

N Engl J Med. 2016 Apr 28;374(17):1688-9. No abstract available.

PMID:
27135095
17.

Influence of antibiotic-regimens on intensive-care unit-mortality and liver-cirrhosis as risk factor.

Friedrich-Rust M, Wanger B, Heupel F, Filmann N, Brodt R, Kempf VA, Kessel J, Wichelhaus TA, Herrmann E, Zeuzem S, Bojunga J.

World J Gastroenterol. 2016 Apr 28;22(16):4201-10. doi: 10.3748/wjg.v22.i16.4201.

18.

Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.

Maasoumy B, Vermehren J, Welker MW, Bremer B, Perner D, Höner Zu Siederdissen C, Deterding K, Lehmann P, Cloherty G, Reinhardt B, Pawlotsky JM, Manns MP, Zeuzem S, Cornberg M, Wedemeyer H, Sarrazin C.

J Hepatol. 2016 Sep;65(3):473-82. doi: 10.1016/j.jhep.2016.04.006. Epub 2016 Apr 13.

PMID:
27085252
19.

Intraductal biopsies in indeterminate biliary stricture: Evaluation of histopathological criteria in fluoroscopy- vs. cholangioscopy guided technique.

Walter D, Peveling-Oberhag J, Schulze F, Bon D, Zeuzem S, Friedrich-Rust M, Albert JG.

Dig Liver Dis. 2016 Jul;48(7):765-70. doi: 10.1016/j.dld.2016.03.013. Epub 2016 Mar 26.

PMID:
27067926
20.

NOD2 Risk Variants and Pathological Bacterial Translocation in Decompensated Cirrhosis.

Bruns T, Reuken PA, Stengel S, Gerber L, Appenrodt B, Schade JH, Lammert F, Zeuzem S, Stallmach A.

Dig Dis Sci. 2016 Jul;61(7):2142-4. doi: 10.1007/s10620-016-4151-0. Epub 2016 Apr 6. No abstract available.

PMID:
27052012
Items per page

Supplemental Content

Loading ...
Write to the Help Desk